Literature DB >> 29232721

The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease.

Cormac J McDonnell1, Erin E Soule1, Patrick T Walsh2,3, James S O'Donnell1, Roger J S Preston1.   

Abstract

Tissue injury prompts the initiation of host defense responses to limit blood loss, restrict pathogen entry, and promote repair. Biochemical and cellular pathways that lead to blood coagulation serve a fundamental role in generating a physical barrier at the wound site, but have also evolved to promote immune response to injury. Similarly, anticoagulant pathways that attenuate clot formation also regulate innate and adaptive immune responses. Of particular importance is activated protein C (APC) which serves as a principal regulator of thrombin generation, shapes the innate immune response to infection, and has been shown to contribute to the adaptive immune response in several preclinical models of autoimmune disease. APC controls blood coagulation by proteolytic degradation of procoagulant activated cofactors essential for fibrin clot development, but also cleaves multiple additional substrates and interacts with cell surface receptors to exert additional physiologically important roles. In this review, we focus on the molecular mechanisms utilized by APC to limit inflammation and, in particular, current understanding of the basis for APC anticoagulant and signaling activities. In particular, we provide an overview of established and emerging signaling pathways initiated by APC on endothelial cells, monocytes, neutrophils, dendritic cells, and T cells to control and regulate immune cell physiology. Finally, we consider the impact of APC activity in the context of both acute and chronic inflammatory disease, and the continuing efforts to harness the immunoregulatory properties of recombinant APC for therapeutic use. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29232721     DOI: 10.1055/s-0037-1608910

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

1.  Apolipoprotein A-I enhances activated protein C cytoprotective activity.

Authors:  Eimear M Gleeson; Aisling M Rehill; Orla Willis Fox; Fionnuala Ni Ainle; Cormac J McDonnell; Hannah J Rushe; Seán McCluskey; James S O'Donnell; Roger J S Preston
Journal:  Blood Adv       Date:  2020-06-09

Review 2.  Regulation of immune cell signaling by activated protein C.

Authors:  Laura D Healy; Rachel A Rigg; John H Griffin; Owen J T McCarty
Journal:  J Leukoc Biol       Date:  2018-03-30       Impact factor: 4.962

3.  Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin.

Authors:  Vijayalakshmi Sridharan; Kristin A Johnson; Reid D Landes; Maohua Cao; Preeti Singh; Gail Wagoner; Abdallah Hayar; Emily D Sprick; Kayla A Eveld; Anusha Bhattacharyya; Kimberly J Krager; Nukhet Aykin-Burns; Hartmut Weiler; Jose A Fernández; John H Griffin; Marjan Boerma
Journal:  PLoS One       Date:  2021-05-24       Impact factor: 3.240

Review 4.  The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases.

Authors:  Di Ren; Hemant Giri; Ji Li; Alireza R Rezaie
Journal:  Int J Mol Sci       Date:  2019-04-10       Impact factor: 5.923

Review 5.  Protein C Pathway in Paediatric and Neonatal Sepsis.

Authors:  Hassan Eliwan; Murwan Omer; Ellen McKenna; Lynne A Kelly; Beatrice Nolan; Irene Regan; Eleanor J Molloy
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

6.  Activated protein C and PAR1-derived and PAR3-derived peptides are anti-inflammatory by suppressing macrophage NLRP3 inflammasomes.

Authors:  Laura D Healy; José A Fernández; Laurent O Mosnier; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

7.  COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation.

Authors:  John H Griffin; Patrick Lyden
Journal:  Res Pract Thromb Haemost       Date:  2020-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.